The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: Studies with rats, hepatic cytochrome P450 reductase null (HRN™) mice and pure enzymes

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2014, Pages 284-306

  Stiborová, Marie ^a   Černá, Věra ^a   Moserová, Michaela ^a   Mrízová, Iveta ^a   Arlt, Volker M ^b   Frei, Eva ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anticancer drug ellipticine; Covalent DNA adducts; Cytochrome P450 mediated DNA damage; Enzymes metabolizing ellipticine in vitro and in vivo

Indexed keywords

CYCLOOXYGENASE 1; CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 1B1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; DNA DIRECTED RNA POLYMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ELLIPTICINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFOTRANSFERASE 1A1; TUMOR SUPPRESSOR PROTEIN; ANTINEOPLASTIC AGENT; CYTOCHROME P450 1A1; ELLIPTICINE DERIVATIVE; UNCOUPLING PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL CYCLE ARREST; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DRUG DETOXIFICATION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; ESCHERICHIA COLI; GENOTOXICITY; HUMAN; METABOLIC CAPACITY; MICROSOME; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; REVIEW; THIN LAYER CHROMATOGRAPHY; WISTAR RAT; ANIMAL; DEFICIENCY; DRUG EFFECTS; GENETICS; LIVER CELL; METABOLISM; MOUSE; RAT;

ANIMALIA; MUS; RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP1A1; DNA DAMAGE; ELLIPTICINES; HEPATOCYTES; MICE; RATS; UNCOUPLING AGENTS;

EID: 84919790516     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16010284     Document Type: Review

References (100)

1. Stiborova, M.; Bieler, C. A.; Wiessler, M.; Frei, E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem. Pharmacol. 2001, 62, 1675-1684.
2. Stiborova, M.; Rupertova, M.; Schmeiser, H. H.; Frei, E. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2006, 150, 13-23.
3. Stiborova, M.; Rupertova, M.; Frei, E. Cytochrome P450-and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim. Biophys. Acta 2011, 1814, 175-185.
4. Kizek, R.; Adam, V.; Hrabeta, J.; Eckschlager, T.; Smutny, S.; Burda, J. V.; Frei, E.; Stiborova, M. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances. Pharmacol. Ther. 2012, 133, 26-39.
5. Auclair, C. Multimodal action of antitumor agents on DNA: The ellipticine series. Arch. Biochem. Biophys. 1987, 259, 1-14.
6. Garbett, N. C.; Graves, D. E. Extending nature's leads: The anticancer agent ellipticine. Curr. Med. Chem. Anti-Cancer Agents 2004, 4, 149-172.
7. Kuo, P. L.; Hsu, Y. L.; Chang, C. H.; Lin, C. C. The antiproliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anti-Cancer Drugs 2005, 16, 789-795.
8. Russell, E. G.; O'Sullivan, E. C.; Miller, C. M.; Stanicka, J.; McCarthy, F. O.; Cotter, T. G. Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells. Investig. New Drugs 2014, 32, 1113-1122.
9. Kim, J. Y.; Lee, S. G.; Chung, J. Y.; Kim, Y. J.; Park, J. E.; Koh, H.; Han, M. S.; Park, Y. C.; Yoo, Y. H.; Kim, J. M. Ellipticine induces apoptosis in human endometrial cancer cells: The potential involvement of reactive oxygen species and mitogen-activated protein kinases. Toxicology 2011, 289, 91-102.
10. Kuo, P. L.; Hsu, Y. L.; Chang, C. H.; Lin, C. C. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett. 2005, 223, 293-301.
11. Ohashi, M.; Sugikawa, E.; Nakanishi, N. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism. Jpn. J. Cancer Res. 1995, 86, 819-829.
12. Shi, L. M.; Myers, T. G.; Fan, Y.; O'Conno, R. P. M.; Paull, K. D.; Friend, S. H.; Weinstein, J. N. Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol. Pharmacol. 1998, 53, 241-251.
13. Kuo, P. L.; Kuo, Y. C.; Hsu, Y. L.; Cho, C. Y.; Lin, C. C. Ellipticine induced apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci. 2006, 78, 2550-2557.
14. Martinkova, E.; Maglott, A.; Leger, D. Y.; Bonnet, D.; Stiborova, M.; Takeda, K.; Martin, S.; Dontenwill, M. α5β1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int. J. Cancer 2010, 127, 1240-1248.
15. Sugikawa, E.; Hosoi, T.; Yazaki, N.; Gamanuma, N.; Nakanishi, N.; Ohashi, M. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res. 1999, 19, 3099-3108.
16. Peng, Y.; Li, C.; Chen, L.; Sebti, S.; Chen, J. Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003, 22, 4478-4487.
17. Savorani, C.; Manfé, V.; Biskup, E.; Gniadecki, R. Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage. Leuk. Lymphoma 2014, 4, 1-9.
18. Fang, K.; Chen, S. P.; Lin, C. W.; Cheng, W. C.; Huang, H. T. Ellipticine-induced apoptosis depends on Akt translocation and signaling in lung epithelial cancer cells. Lung Cancer 2009, 63, 227-234.
19. Wang, F.; Liu, J.; Robbins, D.; Morris, K.; Sit, A.; Liu, Y. Y.; Zhao, Y. Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells. Apoptosis 2011, 16, 301-310.
20. Miller, C. M.; McCarthy, F. O. Isolation, biological activity and synthesis of the natural product ellipticine and related pyridocarbazoles. RSC Adv. 2012, 2, 8883-8918.
21. Fritsche, M.; Haessler, C.; Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993, 8, 307-318.
22. Xu, G. W.; Mawji, I. A.; Macrae, C. J.; Koch, C. A.; Datti, A.; Wrana, J. L.; Dennis, J. W.; Schimmer, A. D. A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization. Apoptosis 2008, 13, 413-422.
23. Kohn, K. W.; Waring, M. J.; Glaubiger, D.; Friedman, C. A. Intercalative binding of ellipticine to DNA. Cancer Res. 1975, 35, 71-76.
24. Patel, N.; Bergman, J.; Gräslund, A. 1H-NMR studies of the interaction between a self-complementary deoxyoligonucleotide duplex and indolo[2, 3-b]quinoxaline derivatives active against herpes virus. Eur. J. Biochem. 1991, 197, 597-604.
25. Chu, Y.; Hsu, M. T. Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. Nucleic Acids Res. 1992, 20, 4033-4038.
26. Singh, M. P.; Hill, G. C.; Peoch, D.; Rayner, B.; Inabach, J. L.; Lown, J. W. High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 1994, 33, 10271-10285.
27. Belehradek, J., Jr.; Fermandjian, S. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J. Biol. Chem. 1991, 266, 1820-1829.
28. Froelich-Ammon, S. J.; Patchan, M. W.; Osheroff, N.; Thompson, R. B. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J. Biol. Chem. 1995, 270, 14998-5004.
29. Andrews, W. J.; Panova, T.; Normand, C.; Gadal, O.; Tikhonova, I. G.; Panov, K. I. Old drug, new target: Ellipticines selectively inhibit RNA polymerase I transcription. J. Biol. Chem. 2013, 288, 4567-4582.
30. Ghosh, S.; Kar, A.; Chowdhury, S.; Dasgupta, D. Ellipticine binds to a human telomere sequence: An additional mode of action as a putative anticancer agent? Biochemistry 2013, 52, 4127-4137.
31. Stiborová, M.; Sejbal, J.; Borek-Dohalská, L.; Aimová, D.; Poljaková, J.; Forsterová, K.; Rupertová, M.; Wiesner, J.; Hudecek, J.; Wiessler, M.; et al. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res. 2004, 64, 8374-8380.
32. Stiborová, M.; Poljaková, J.; Ryslavá, H.; Dracínský, M.; Eckschlager, T.; Frei, E. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int. J. Cancer 2007, 120, 243-251.
33. Stiborová, M.; Rupertová, M.; Aimová, D.; Ryslavá, H.; Frei, E. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 2007, 236, 50-60.
34. Stiborová, M.; Indra, R.; Moserová, M.; Cerná, V.; Rupertová, M.; Martínek, V.; Eckschlager, T.; Kizek, R.; Frei, E. Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N, O-acetyltransferases. Chem. Res. Toxicol. 2012, 25, 1075-1085.
35. Kotrbová, V.; Mrázová, B.; Moserová, M.; Martínek, V.; Hodek, P.; Hudeček, J.; Frei, E.; Stiborová, M. Cytochrome b5 shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy. Biochem. Pharmacol. 2011, 82, 669-680.
36. Stiborova, M.; Frei, E. Ellipticines as DNA-targeted chemotherapeutics. Curr. Med. Chem. 2014, 21, 575-591.
37. Stiborová, M.; Breuer, A.; Aimová, D.; Stiborová-Rupertová, M.; Wiessler, M.; Frei, E. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int. J. Cancer 2003, 107, 885-890.
38. Stiborová, M.; Stiborová-Rupertová, M.; Bořek-Dohalská, L.; Wiessler, M.; Frei, E. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem. Res. Toxicol. 2003, 16, 38-47.
39. Stiborová, M.; Poljakova, J.; Martínková, E.; Ulrichová, J.; Šimánek, V.; Dvořák, Z.; Frei, E. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5. Toxicology 2012, 302, 233-241.
40. Kotrbová, V.; Aimová, D.; Březinová, A.; Janouchová, K.; Poljaková, J.; Hodek, P.; Frei, E.; Stiborová, M. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. Neuro Endocrinol. Lett. 2006, 27 (Suppl. 2), 18-20.
41. Stiborova, M.; Poljakova, J.; Mrizova, I.; Borek-Dohalska, L; Eckschlager, T.; Adam, V.; Kizek, R.; Frei, E. Expression levels of enzymes metabolizing an anticancer drug ellipticine determined by electromigration assays influence its cytotoxicity to cancer cells-A comparative study. Int. J. Electrochem. Sci. 2014, 9, 5675-5689.
42. Poljaková, J.; Frei, E.; Gomez, J. E.; Aimová, D.; Eckschlager, T.; Hraběta, J.; Stiborová, M. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett. 2007, 252, 270-279.
43. Poljaková, J.; Eckschlager, T.; Hraběta, J.; Hřebačková, J.; Smutný, S.; Frei, E.; Martínek, V.; Kizek, R.; Stiborová, M. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem. Pharmacol. 2009, 77, 1466-1479.
44. Poljakova, J.; Hrebackova, J.; Dvořákova, M.; Moserova, M.; Eckschlager, T.; Hrabeta, J.; Göttlicherova, M.; Kope Jtkova, B.; Frei, E.; Kizek, R.; et al. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. Neuro Endocrinol. Lett. 2011, 32 (Suppl. 1), 101-116.
45. Poljaková, J.; Eckschlager, T.; Kizek, R.; Frei, E.; Stiborová, M. Electrochemical determination of enzymes metabolizing ellipticine in thyroid cancer cells-A tool to explain the mechanism of ellipticine toxicity to these cells. Int. J. Electrochem. Sci. 2013, 8, 1573-1585.
46. Martinkova, E.; Dontenwill, M.; Frei, E.; Stiborová, M. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. Neuro Endocrinol. Lett. 2009, 30 (Suppl. 1), 60-66.
47. Poljaková, J.; Dračínský, M.; Frei, E.; Hudeček, J., Stiborová, M. The effect of pH on peroxidase-mediated oxidation of and DNA-adduct formation by ellipticine. Collect. Czech Chem. Commun. 2006, 71, 1169-1185.
48. Stiborová, M.; Arlt, V. M.; Henderson, C. J.; Wolf, C. R.; Kotrbová, V.; Moserová, M.; Hudecek, J.; Phillips, D. H.; Frei, E. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: Studies with the hepatic NADPH: Cytochrome P450 reductase null mouse. Toxicol. Appl. Pharmacol. 2008, 226, 318-327.
49. Stiborová, M.; Moserová, M.; Mrázová, B.; Kotrbová, V.; Frei, E. Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: Additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney. Neuro Endocrinol. Lett. 2010, 31 (Suppl. 2), 26-35.
50. Stiborová, M.; Eckschlager, T.; Poljaková, J.; Hraběta, J.; Adam, V.; Kizek, R.; Frei, E. The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Curr. Med. Chem. 2012, 19, 4218-4238.
51. Vranová, I.; Moserová, M.; Hodek, P.; Kizek, R.; Frei, E.; Stiborová, M. The anticancer drug ellipticine induces cytochromes P450 1A1, 1A2 and 3A, cytochrome b5 and NADPH: Cytochrome P450 in rat liver, kidney and lung. Int. J. Electrochem. Sci. 2013, 8, 1586-1597.
52. Chadwick, M.; Silveira, D. M.; Platz, B. R.; Hayes, D. Comparative physiological disposition of ellipticine in several animal species after intravenous administration. Drug Metab. Dispos. 1978, 6, 528-541.
53. Branfam, A. R.; Bruni, R. J.; Reihold, V. N.; Silveira, D. M.; Chadwick, M.; Yesair, D. W. Characterization of metabolites of ellipticine in rat bile. Drug Metab. Dispos. 1978, 6, 542-548.
54. Ismail, M. A.; Sanders, K. J.; Fennell, G. C.; Latham, H. C.; Wormell, P.; Rodger, A. Spectroscopic studies of 9-hydroxyellipticine binding to DNA. Biopolymers 1998, 46, 127-143.
55. Fossé, P.; René, B.; le Bret, M.; Paoletti, C.; Saucier, J. M. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res. 1991, 19, 2861-2868.
56. Fossé, P.; René, B.; Charra, M.; Paoletti, C.; Saucier, J. M. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: Structure-activity relationships. Mol. Pharmacol. 1992, 42, 590-595.
57. Hofle, G.; Glase, N.; Leibold, T.; Sefkow, M. Epothilone A-D and their thiazole-modified analogs as novel anticancer agents. Pure Appl. Chem. 1999, 71, 2019-2024.
58. Moserova, M.; Kotrbova, V.; Rupertova, M.; Naiman, K.; Hudecek, J.; Hodek, P.; Frei, E.; Stiborova, M. Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA. Neuro Endocrinol. Lett. 2008, 29, 728-732.
59. Martínek, V.; Sklenár, J.; Dracínsky, M.; Sulc, M.; Hofbauerová, K.; Bezouska, K.; Frei, E.; Stiborová, M. Glycosylation protects proteins against free radicals generated from toxic xenobiotics. Toxicol. Sci. 2010, 117, 59-74.
60. Stiborová, M.; Borek-Dohalská, L.; Aimová, D.; Kotrbová, V.; Kukacková, K.; Janouchová, K.; Rupertová, M.; Ryslavá, H.; Hudecek, J.; Frei, E. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes-Similarity between human and rat systems. Gen. Physiol. Biophys. 2006, 25, 245-261.
61. Stiborova, M.; Cerna, V.; Moserova, M.; Arlt, V. M.; Frei, E. The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice. Neuro Endocrinol. Lett. 2013, 34 (Suppl. 2), 43-54.
62. Henderson, C. J.; Otto, D. M.; Carrie, D.; Magnuson, M. A.; McLaren, A. W.; Rosewell, I.; Wolf, C. R. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 2003, 278, 13480-13486.
63. Arlt, V. M.; Stiborova, M.; Henderson, C. J.; Osborne, M. R.; Bieler, C. A.; Frei, E.; Martinek, V.; Sopko, B.; Wolf, C. R.; Schmeiser, H. H.; et al. Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H: quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res. 2005, 65, 2644-2652.
64. Arlt, V. M.; Henderson, C. J.; Wolf, C. R.; Schmeiser, H. H.; Phillips, D. H.; Stiborova, M. Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: Evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett. 2006, 234, 220-2231.
65. Arlt, V. M.; Stiborová, M.; Henderson, C. J.; Thiemann, M.; Frei, E.; Aimová, D.; Singh, R.; Gamboa da Costa, G.; Schmitz, O. J.; Farmer, P. B.; et al. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: Experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 2008, 29, 656-665.
66. Arlt, V. M.; Poirier, M. C.; Sykes, S. E.; John, K.; Moserova, M.; Stiborova, M.; Wolf, C. R.; Henderson, C. J.; Phillips, D. H. Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling. Toxicol. Lett. 2012, 213, 160-166.
67. Pass, G. J.; Carrie, D.; Boylan, M.; Lorimore, S.; Wright, E.; Houston, B.; Henderson, C. J.; Wolf, C. R. Role of hepatic cytochrome P450s in the pharmacokinetics and toxicity of cyclophosphamide: Studies with the hepatic cytochrome P450 reductase null mouse. Cancer Res. 2005, 65, 4211-4217.
68. Xiao, Y.; Ge, M.; Xue, X.; Wang, H.; Wu, X.; Li, L.; Liu, L.; Qi, X.; Zhang, Y.; Li, Y.; et al. Detoxication role of hepatic cytochrome P450s in the kidney toxicity induced by aristolochic acid. Kidney Int. 2008, 73, 1231-1239.
69. Levová, K.; Moserová, M.; Kotrbová, V.; Šulc, M.; Henderson, C. J.; Wolf, C. R.; Phillips, D. H.; Frei, E.; Schmeiser, H. H.; Mareš, J.; et al. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: Studies with the hepatic NADPH: cytochrome P450 reductase null (HRN) mouse model. Toxicol. Sci. 2011, 121, 43-56.
70. Eling, T. E.; Thompson, D. C.; Foureman, G. L.; Curtis, J. F.; Hughes, M. F. Prostaglandin H synthase and xenobiotic oxidation. Annu. Rev. Pharmacol. Toxicol. 1990, 30, 1-45.
71. Eling, T. E.; Curtis, J. F. Xenobiotic metabolism by prostaglandin H synthase. Pharm. Ther. 1992, 53, 261-273.
72. Stiborova, M.; Frei, E.; Hodek, P.; Wiessler, M.; Schmeiser, H. H. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH: cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int. J. Cancer 2005, 113, 189-197.
73. Downie, D.; McFadyen, M. C.; Rooney, P. H.; Cruickshank, M. E.; Parkin, D. E.; Miller, I. D.; Telfer, C.; Melvin, W. T.; Murray, G. I. Profiling cytochrome P450 expression in ovarian cancer: Identification of prognostic markers. Clin. Cancer Res. 2005, 11, 7369-7735.
74. Saarikoski, T.; Rivera, S. P.; Hankinson, O.; Husgafvel-Pursiainen, K. CYP2S1: A short review. Toxicol. Appl. Pharmacol. 2005, 207, 62-69.
75. Bui, P. H.; Hankinson, O. Functional characterization of human cytochrome P450 2S1 using a synthetic gene-expressed protein in Escherichia coli. Mol. Pharmacol. 2009, 76, 1031-1043.
76. Bui, P. H.; Hsu, E. L.; Hankinson, O. Fatty acid hydroperoxides support cytochrome P450 2S1-mediated bioactivation of benzo[a]pyrene-7, 8-dihydrodiol. Mol. Pharmacol. 2009, 76, 1044-1052.
77. Mrizová, I.; Moserová, M.; Milichovsky, J.; Šulc, M.; Guengerich, F. P.; Stiborová, M. Heterologous expression of cytochrome P450 2S1 in Escherichia coli. Interdisc. Toxicol. 2014, 7 (Suppl. 1), 66.
78. Stiborova, M.; Moserova, M.; Černá, V.; Indra, R.; Dračínský, M.; Šulc, M.; Henderson, C. J.; Wolf, C. R.; Schmeiser, H. H.; Phillips, D. H.; et al. Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH: P450 oxidoreductase conditions. Toxicology 2014, 318, 1-12.
79. Rendic, S.; DiCarlo, F. J. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 1997, 29, 413-480.
80. Ueng, Y.-F.; Kuwabara, T.; Chun, Y.-J.; Guengerich, F. P. Cooperativity in oxidation catalyzed by cytochrome P450 3A4. Biochemistry 1997, 36, 370-381.
81. Patterson, L. H.; McKeown, S. R.; Robson, T.; Gallagher, R.; Raleigh, S. M.; Orr, S. Antitumor prodrug development using cytochrome P450 (CYP) mediated activation. Anti-Cancer Drug Des. 1999, 14, 473-486.
82. Murray, G. I.; Melvin, W. T.; Burke, M. Cytochrome P450 expression in tumors. J. Pathol. 1995, 176, 323-324.
83. El-Rayes, B. F.; Ali, S.; Heilbrun, L. K.; Lababidi, S.; Bouwman, S.; Vischer, D.; Philip, P. A. Cytochrome P450 and glutathione transferase expression in human breast cancer. Clin. Cancer Res. 2003, 9, 1705-1709.
84. Godschalk, R. W. L.; Moonen, E. J. C.; Schilderman, P. A. E. L.; Broekmans, W. M. R.; Kleinjans, J. C. S.; van Schooten, F. J. Exposure-route-dependent DNA adduct formation by polycyclic aromatic hydrocarbons. Carcinogenesis 2000, 21, 87-92.
85. Poirier, M. C. Chemical-induced DNA damage and human cancer risk. Nat. Rev. 2004, 4, 630-637.
86. Randerath, K.; Haglund, R. E.; Phillips, D. H.; Reddy, M. V. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice. Carcinogenesis 1984, 5, 1613-1622.
87. Ross, J. A.; Nelson, G. B.; Wilson, K. H.; Rabinowitz, J. R.; Galati, A.; Stoner, G. D.; Nesnow, S.; Mass, M. J. Adenomas induced by polycyclic aromatic hydrocarbons in strain A/J mouse lung correlate with time-integrated DNA adduct levels. Cancer Res. 1995, 55, 1039-1044.
88. Smith, B. A.; Fullerton, N. F.; Heflich, R. H.; Beland, F. A. DNA adduct formation and T-lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1, 6-dinitropyrene. Cancer Res. 1995, 55, 2316-2324.
89. Yamazaki, H.; Gillam, E. M.; Dong, M. S.; Johnson, W. W.; Guengerich, F. P.; Shimada, T. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: Effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Arch. Biochem. Biophys. 1997, 342, 329-337.
90. Yamazaki, H.; Shimada, T.; Martin, M. V.; Guengerich, F. P. Stimulation of cytochrome P450 reactions by apo-cytochrome b5: Evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase. J. Biol. Chem. 2001, 276, 30885-30891.
91. Schenkman, J. B.; Jansson, I. The many roles of cytochrome b5. Pharmacol. Ther. 2003, 97, 139-152.
92. Zhang, H.; Myshkin, E.; Waskell, L. Role of cytochrome b5 in catalysis by cytochrome P450 2B4. Biochem. Biophys. Res. Commun. 2005, 338, 499-506.
93. Zhang, H.; Im, S. C.; Waskell, L. Cytochrome b5 increases the rate of product formation by cytochrome P450 2B4 and competes with cytochrome P450 reductase for a binding site on cytochrome P450 2B4. J. Biol. Chem. 2007, 282, 29766-29776.
94. Kotrbová, V.; Aimová, D.; Ingr, M.; Borek-Dohalská, L.; Martínek, V.; Stiborová, M. Preparation of a biologically active apo-cytochrome b5 via heterologous expression in Escherichia coli. Protein Expr. Purif. 2009, 66, 203-209.
95. Rendic, S.; Guengerich, F. P. Contributions of human enzymes in carcinogen metabolism. Chem. Res. Toxicol. 2012, 25, 1316-1383.
96. Aimová, D.; Svobodová, L.; Kotrbová, V.; Mrázová, B.; Hodek, P.; Hudeček, J.; Václavíková, R.; Frei, E.; Stiborová, M. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab. Dispos. 2007, 35, 1926-1934.
97. Finn, R. D.; McLaughlin, L. A.; Ronseaux, S.; Rosewell, I.; Houston, J. B.; Henderson, C. J.; Wolf, C. R. Defining the in vivo role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5. J. Biol. Chem. 2008, 283, 31385-31393.
98. Henderson, C. J.; McLaughlin, L. A.; Wolf, C. R. Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system. Mol. Pharmacol. 2013, 83, 1209-1217.
99. Ma, J.; Waxman, D. J. Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol. Cancer Ther. 2007, 6, 2879-2890.
100. Lu, H.; Chen, C. S.; Waxman, D. J. Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Ther. 2009, 16, 393-404.